Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

a move that was hurting its margins and long-term prospects. An expensive acquisition strategy that saw Pfizer Inc. (NYSE:PFE) spending nearly $70 billion did not go well with the investors.

a move that was hurting its margins and long-term prospects. An expensive acquisition strategy that saw Pfizer Inc. (NYSE:PFE) spending nearly $70 billion did not go well with the investors.

Considering the analyst consensus, Pfizer's shares are currently trading below the consensus price target, suggesting some skepticism about near-term growth prospects. The positive news of the ...